Insights and Innovations
Join Maryam Ahmadi for a Presentation and Poster Showcase
SPEAKER PRESENTATION
Accelerating Drug Development: Introducing 2nd Generation Cyto-Mine®, Automated Multi-Laser Droplet Microfluidic Platform
Thurs. 7 Nov., 16:10pm
Track: Protein Process Development
POSTER PRESENTATION
Picodroplets for Biologics Discovery and Cell Line Development: Accelerating the Discovery and Development Process
6 Nov. 12:45 – 13:45
6 Nov. 16:35 – 17:15
7 Nov. 10:00 – 10:45
7 Nov. 12:45 – 13:55
Poster #B103 in the Poster Zone
View our latest poster presentation featuring Cyto-Mine®Chroma
Highlights Include:
Faster project completion
Multiplexing capabilities
Rapid identification and isolation of rare cells
Assurance of monoclonality in selected cells
About Maryam Ahmadi
Dr. Maryam Ahmadi, Director of Science at Sphere Fluidics, brings over 17 years of comprehensive experience in both industry and academia to her role. With a decade-long tenure at a Contract Research Organization (CRO), Maryam honed her skills in managing diverse projects.
Notably, as the former Director of Bioassay at Abzena, she led a team specializing in bespoke Immunology and Bioassay for external clients. Her responsibilities included the development of service lines crucial for testing and de-risking therapeutics, such as PK studies, MHC-associated peptide proteomics (MAPPs), and Cytokine Release Assay for therapeutic antibodies and antibody-drug conjugates.
Maryam’s expertise spans Immunology and Tumor Biology, underscored by her proficiency in designing and overseeing tailored R&D initiatives. Her academic journey includes a postdoctoral research position at University College London (UCL), where she delved into tumor-specific immune responses. She holds a PhD in Tumor Immunology from the University of Bristol, UK.
Visit the event website to register now
Join us at PEGS Europe 2024, recognized as the best biologics technology meeting in Europe, where over 1,500 industry leaders, scientists, and innovators gather to explore the latest advancements in protein and antibody engineering. This year’s event features expanded coverage on cutting-edge topics such as AI and machine learning, multispecific antibodies, antibody-drug conjugates, and a dedicated oncology stream.
